XS 001
Alternative Names: hiPSC-DAP; XS-001; XS_001Latest Information Update: 13 Dec 2023
At a glance
- Originator XellSmart Biomedical (Suzhou)
- Class Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 24 Nov 2023 Preclinical trials in Parkinson's disease in China (Intracerebral) before November 2023 (XellSmart Biomedical pipeline, November 2023)
- 24 Nov 2023 XellSmart Biomedical plans a phase I trial for Parkinson's disease (Treatment experienced) in China (Intracerebral, Injection) in November 2023 (NCT06145711)